BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Innova Biosciences Develops Site-Specific Bioconjugation Technology


9/3/2013 11:05:32 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

September 03, 2013 -- Innova Biosciences, the inventor of the world’s easiest to use antibody labeling kits, is pleased to announce the launch of a site-specific bioconjugation technology for attaching antibodies to gold nanoparticles.

Innova’s core business is ‘bioconjugation’ – the joining of two molecules to form a hybrid ‘conjugate’. Conjugates are used in diagnostic tests in hospitals and research labs around the world and in consumer items such as pregnancy test kits. Traditional methods for producing gold conjugates do not provide any control over the orientation of antibodies on the surface of the gold, which may lead to poor performance. Innova’s latest conjugation kit, InnovaCoat® Gold-Hydrazide, allows antibodies to be conjugated via the Fc region, resulting in functional orientation on the nanoparticle surface and enhanced assay sensitivity.

Commenting on the launch of the new conjugation kit Dr Nick Gee, CEO of Innova Biosciences said: “In clinical diagnostics and point-of-care testing there is a desire for more sensitive detection systems to achieve earlier diagnosis and better treatment outcomes, for the benefit of human and veterinary health. This new product combines InnovaCoat® gold nanoparticle stabilisation technology and antibody orientation technology to enhance the performance of antibody-based diagnostic reagents.”

About Innova Biosciences Limited

Innova Biosciences is a growing, dynamic, ISO 9001:2008 business based in Cambridge, UK. At the core of Innova's business are the Lightning-Link®, InnovaCoat® and Thunder-Link® technologies, which simplify the production of antibody-based reagents. The expanding portfolio is sold to research laboratories, pharmaceutical companies, biotechnology companies and diagnostic companies worldwide. For more information, please see www.innovabiosciences.com.

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES